Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BL M07D1

Next Previous
X
Search
Drug Profile

BL M07D1

Alternative Names: BL-M07D1

Latest Information Update: 26 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA damage stimulants; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Gastric cancer

Highest Development Phases

  • Phase III HER2 positive breast cancer
  • Phase I/II Gynaecological cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Gastric cancer

Most Recent Events

  • 19 Jun 2024 Phase-II clinical trials in HER2-positive-breast-cancer (Combination therapy, First-line therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in China (IV) (NCT06445400)
  • 31 May 2024 Sichuan Baili Pharmaceutical plans a phase II trial for HER2-positive-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy, Monotherapy) in China (IV, Infusion) (NCT06445400)
  • 21 May 2024 Sichuan Baili Pharmaceutical plans phase II trial in Oesophageal cancer and Gastric cancer (Late-stage disease, Metastatic disease) in China in June 2024 (IV) (NCT06423885)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top